Business context and reporting period
USANA Health Sciences, Inc. is a global direct-selling nutrition, personal health, and skincare company. This Form 10-Q covers the quarter and six months ended July 1, 2023; the supplied request metadata says 2022 Q2, but the filing itself reports 2023 Q2 and compares results with periods ended July 2, 2022. Amounts below are in U.S. dollars.
The company reported approximately 487,000 active customers, down 12.9% year over year. About 89.8% of first-half sales were outside the United States.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | First half 2023 | First half 2022 |
|---|---|---|---|---|
| Net sales | $238.2 million | $264.5 million | $486.6 million | $537.3 million |
| Gross margin | 81.8% | 81.3% | 81.1% | 81.2% |
| Operating earnings | $24.4 million | $29.4 million | $51.2 million | $62.4 million |
| Net earnings | $17.3 million | $19.2 million | $35.7 million | $41.6 million |
| Diluted EPS | $0.89 | $1.00 | $1.84 | $2.15 |
Q2 associate incentives were 43.0% of sales, versus 45.1% a year earlier; selling, general and administrative expenses were $68.1 million, up $1.7 million. The Q2 effective tax rate was 35.5%, compared with 34.6%. First-half operating cash flow was $22.4 million, down from $34.3 million; capital expenditures were $5.7 million.
At July 1, 2023, cash and cash equivalents were $300.2 million, current assets $387.6 million, and current liabilities $113.8 million. The company had no borrowings under its $75 million revolving credit facility. The facility matures in August 2025 and is subject to financial covenants.
Material changes and management commentary
- Q2 sales fell 9.9% year over year; first-half sales fell 9.5%. Management attributed the decline primarily to fewer active customers, partly offset by modest price increases. Foreign exchange reduced Q2 sales by an estimated $9.6 million and first-half sales by $27.9 million.
- Q2 sales declined across all reported regions: Asia Pacific fell 10.9% and Americas and Europe fell 5.3%. Greater China remained the largest region. Management cited a difficult comparison with a prior-year worldwide sales program; the current-year promotion was specific to China.
- Q2 gross margin improved 50 basis points, helped by lower inventory valuation adjustments and favorable production variances, partly offset by mix, lower-sales leverage, and higher material costs. First-half gross margin declined 10 basis points.
- Net earnings declined 9.7% in Q2 and 14.3% in the first half. Management cited lower sales and higher relative operating expenses; Q2 SG&A also increased in absolute dollars due mainly to meeting and event costs.
- Cash increased by $11.8 million from year-end 2022. First-half operating cash flow was reduced in part by payments of accrued associate incentives and the prior-year employee bonus. No shares were repurchased in the first half of 2023.
Outlook, risks, and unusual items
The filing provides no specific revenue or earnings guidance. Management stated that cash balances, expected operating cash flow, and available credit should be sufficient for ordinary operating and capital needs for the foreseeable future, while noting that adverse conditions or unusual capital needs could require financing. Management also said it may consider share repurchases and acquisitions or investments.
Key risks cited include dependence on direct selling and independent Associates; regulation of direct selling, particularly in China; foreign-exchange volatility; macroeconomic and consumer-spending pressures; supply-chain and raw-material risks; data privacy and cybersecurity; debt-covenant compliance; and litigation, tax, and legal matters. Management said ordinary-course legal matters are not currently expected to have a material adverse effect, though outcomes and potential changes in recorded amounts remain uncertain.
In Q2, the seller’s former employee resigned, triggering forfeiture of $548,000 of remaining contingent consideration; the filing describes a related noncash gain. The company also reported a $20 million investment in equity securities without readily determinable fair values, with no impairment or valuation adjustment during the period.
Important facts for investors to verify
- Confirm the intended reporting period: the supplied metadata says 2022 Q2, while the filing covers Q2 2023.
- Track whether the active-customer decline stabilizes, especially in China and Southeast Asia Pacific, and how promotions affect customer activity and sales.
- Assess sales and earnings trends excluding foreign-exchange effects, and the persistence of gross-margin and expense changes.
- Monitor operating cash flow, working-capital movements, cash location and remittance restrictions in China, and compliance with credit-facility covenants.
- Review developments in China-related regulatory and operating risks, legal contingencies, and the carrying value of the private equity investment.